Investigation of Parvovirus B19 IgG and IgM antibodies with ELISA, distribution with regard to age groups and comparison with literature

Year 2018, , 30 - 33, 10.03.2018

Ayşe İnci , Aytül Çorbacıoğlu Esmer

https://doi.org/10.5799/jcei.413067

Abstract

Investigation
of Parvovirus B19 IgG and IgM antibodies with ELISA, distribution with regard
to age groups and comparison with literature

Ayşe İnci,
Aytül Çorbacıoğlu Esmer

 

Objective:
Human
parvovirus is an un-enveloped, linear, single bundle DNA virus 18-26 nm in
diameter which is common worldwide and causes an asymptomatic infection. The
most common clinical manifestation is erythema infectiosum, it may also lead to
aplastic crisis, arthropathy, neutropenia, thrombocytopenia and fetal
infections. In this study, we aimed to determine parvovirus B19 sero-positivity
rates, distribution according to age and contribute to epidemiologic data in
our country.

Patients
and Methods: Results
of pregnant women who were admitted to Kanuni Suleiman Hospital between January
2015 and January 2017, examined for parvovirus B19 infection and whose
parvovirus B19 IgG/IgM antibodies were examined with ELISA method were recorded
from patient files. Parvovirus B19 IgM and parvovirus B19 IgG test results were
retrospectively analyzed. parvovirus B19 IgM and parvovirus B19 IgG were
examined with ELISA method in accordance with recommendations of the
manufacturer.

Results:
A total of 156
pregnant women whose parvovirus B19 IgG/IgM antibodies had been analyzed were
included in the study. While parvovirus B19 IgG was positive in 64.7% of the
patients, parvovirus B19 IgM alone positivity was not detected in any women.
parvovirus B19 IgG and IgM were positive in 3 women. parvovirus B19 IgG
positivity was greatest above 40 years and minimum in 18-25 age group.

Conclusion:
In conclusion,
parvovirus B19 IgG positivity was found similar with that in other countries.
We consider that studies conducted with different groups and in different
regions would contribute to epidemiologic data.

Keywords

Parvovirus B19, pregnancy, ELISA

References

• 1.Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ. 1995; 9;311:1549-52.
• 2. Işık N, Sabahoğlu E, Işık M, Anak S, Ağaçfidan A, Bozkaya E. Follow up of Patients Pre-Diagnosed as parvovirus B19 Infection. Turk Mikrobiyol Cem Derg. 2004;34:62-6.
• 3. Giorgio E, De Oronzo MA, Iozza I. et al. Parvovirus B19 during pregnancy: a review. J Prenat Med. 2010;4: 63–6.
• 4. Tolfvenstam T, Broliden K. parvovirus B19 infection. Semin Fetal Neonatal Med. 2009;14:218-21.
• 5. Enders M, Weidner A, Rosenthal T et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis. 2008;197:58-62.
• 6. Braham S, Gandhi J, Beard S, Cohen B. Evaluation of the Roche Light Cycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections. J Clin Virol. 2004;31:5-10.
• 7. Yetgin S, Elmas SA. Parvovirus-B19 and hematologic disorders. Turk J Hematol. 2010;27:224-33.
• 8.Jordan JA, Huff D, DeLoia JA. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol. 2001;8:288-92.
• 9. Dembinski J, Eis-Hubinger A, Maar J, Schild R, Bartmann P. Long term follow-up of serostatus after maternofetal parvovirus B19 infection. Arch Dis Child. 2003;88:219–21.
• 10. Désilets V, Audibert F; Society of Obstetrician and Gynaecologists of Canada. Investigation and management of non-immune fetal hydrops. J Obstet Gynaecol Can. 2013;35:923-38.
• 11. Türkdağı H,Özdemir M, Baykan M, Baysal B. Investigation of parvovirus B19 various age groups in central Anatolia Region. Mikrobiyol Bul. 2010;44:467-72.
• 12. Aktaş O, Aydın H, Uslu H. Serological prevalence of human parvovirus B19 in diseases or disorders related to different human body systems. Turk J Med Sci. 2016;46:368-73.
• 13. Colak D, Oğunc D, Aktekin M, Başustaoğlu AC, Gultekin M. Seroprevalence of parvovirus B19 antibodies in children between the ages 4-6 years in Ahatlı, Antalya. Klimik Dergisi 1998;2:61-2.
• 14. Sözen E, Bayram A, Onat AM, Balcı İ. The role of Herpesviridea and parvovirus B19 etiology of Ankylosing Spondylitis and Behçet’s Syndrome Turk J Infect 2008;22:75-8.
• 15. Us T, Cetin E, Kaşıfoğlu N, Akgun Y, Bal C. Investigation of the etiologic role of parvovirus B19 by immunologic and molecular methods in rheumatoid arthritis and systemic lupus erythematosus. Turkiye Klinikleri J Med Sci 2013; 33: 334–38.
• 16. Skjoldebrand-Sparre L, Fridell E, Nyman M,Wahren B. A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstet Gynecol Scand 1996;75:336–9.
• 17. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24:513-8.
• 18. Makhseed M, Pacsa A, Ahmed MA, Essa SS. Pattern of parvovirus B 19 infection during different trimesters of pregnancy in Kuwait. Infect Dis Obstet Gynecol. 1999;7:287-92.
• 19.Khameneh ZR, Hanifian H, Barzegari R, Sepehrvand N. Human parvovirus B19 in Iranian pregnant women: A serologic survey. Indian J Pathol Microbiol. 2014;57:442–4.
• 20. Harger JH, Adler SP, Koch WC, Harger GF: Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998;91:413–20.
• 21. Jensen IP, Thorsen P, Jeune B, Moller BR, Vestergaard BF. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors. BJOG. 2000;107:637–43.
• 22. Odland JØ, Sergejeva IV, Ivaneev MD, Jensen IP, Stray-Pedersen B. Seropositivity of cytomegalovirus, parvovirus and rubella in pregnant women and recurrent aborters in Leningrad County, Acta Obstet Gynecol Scand. 2001 ;80:1025-9.
• 23. Karunajeewa H, Siebert D, Hammond R, Garland S, Kelly H: Seroprevalence of varicella zoster virus, parvovirus B19 and Toxoplasma gondii in a Melbourne obstetric population: implications for management. Aust N Z J Obstet Gynaecol 2001;41:23–8.
• 24. Alanen A, Kahala K, Vahlberg T, Koskela P, Vainionpaa R: Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. BJOG. 2005;112:50–6.
• 25. Ziyaeyan M, Rasouli M, Alborzi A. The seroprevalence of parvovirus B19 infection among to-be-married girls, pregnant women, and their neonates in Shiraz, Iran. Jpn J Infect Dis. 2005;58:95-7.
• 26.Van Gessel PH, Gaytant MA, Vossen AC, Galama JM, Ursem NT, Steegers EA, Wildschut HI. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: A prospective study. Eur J Obstet Gynecol Reprod Biol. 2006;128:46-9.
• 27. Hannachi N, Marzouk M, Harrabi I, et al. Seroprevalence of rubella virus, varicella zoster virus, cytomegalovirus and parvovirus B19 among pregnant women in the Sousse region, Tunisia. Bull Soc Pathol Exot. 2011 ;104:62-7.
• 28. Barlinn R, Vainio K, Samdal HH, Nordbø SA, Nøkleby H, Dudman SG. Susceptibility to cytomegalovirus, parvovirus B19 and age-dependent differences in levels of rubella antibodies among pregnant women. J Med Virol. 2014;86:820–6.
• 29. Adam O, Makkawi T, Reber U, Kirberg H, Eis-Hübinger AM. The seroprevalence of parvovirus B19 infection in pregnant women in Sudan. Epidemiol Infect. 2015 ;143:242-8.
• 30. Johargy AK. Seroprevalence of erythrovirus B19 in Saudi pregnant women. J Family Community Med.